Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 12, 2012, Pages

  Liu, Shu Q ^a   Tefft, Brandon J ^a   Roberts, Derek T ^a   Zhang, Li Qun ^b   Ren, Yupeng ^b   Li, Yan Chun ^c   Huang, Yong ^c   Zhang, Di ^a   Phillips, Harry R ^d   Wu, Yu H ^a  

^a Northwestern University   (United States)

^b REHABILITATION INSTITUTE OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiohepatic interaction; Hepatocytes; Myocardial infarction; Myocardial protection; Secretory proteins

Indexed keywords

BONE MORPHOGENETIC PROTEIN BINDING ENDOTHELIAL REGULATOR; CARDIOVASCULAR AGENT; CXCL3 CHEMOKINE; FIBROBLAST GROWTH FACTOR 21; NEUREGULIN 4; OROSOMUCOID; PROTEOGLYCAN 4; RECOMBINANT PROTEIN; SECRETORY PROTEIN; SMALL INTERFERING RNA; TREFOIL FACTOR 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE SILENCING; GENETIC CODE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; UPREGULATION;

ANIMALS; CARRIER PROTEINS; CORONARY STENOSIS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATOCYTES; LIVER; MALE; MICE; MICE, INBRED C57BL; MUCINS; MYOCARDIAL ISCHEMIA; NEUREGULINS; OROSOMUCOID; RNA, SMALL INTERFERING; TIME FACTORS; UP-REGULATION;

EID: 84871258821     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00362.2012     Document Type: Article

References (71)

1. Akhtar S, Benter I. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117: 3623-3632, 2007.
2. Alison M, Golding M, El Lalani N, Sarraf C. Wound healing in the liver with particular reference to stem cells. Philos Trans R Soc Lond B Biol Sci 353: 877-894, 1998.
3. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARγ and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426-437, 2007.
4. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 28: 1176-1179, 1994.
5. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
6. Benjamin IJ, Guo Y, Srinivasan S, Boudina S, Taylor RP, Rajasekaran NS, Gottlieb R, Wawrousek EF, Abel ED, Bolli R. CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice. Am J Physiol Heart Circ Physiol 293: H3201-H3209, 2007.
7. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95: 125-134, 2004.
8. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, Corey DR. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 14: 1139-1143, 2004.
9. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 105: 365-374, 2009.
10. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, Lefer DJ. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation 122: 11-19, 2010.
11. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
12. Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ, Greenberg ME. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 3: 631-643, 2002.
13. Dostálová I, Haluzíková D, Haluzík M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/ type 2 diabetes mellitus. Physiol Res 58: 1-7, 2009.
14. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 120: 117-130, 2003.
15. Fazel SS, Chen L, Angoulvant D, Li SH, Weisel RD, Keating A, Li RK. Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB J 22: 930-940, 2008.
16. Forbes S, Vig P, Poulsom R, Thomas H, Alison M. Hepatic stem cells. J Pathol 197: 510-518, 2002.
17. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J 55: 23-31, 2008.
18. ATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 40: 1339-1346, 2002.
19. Gilmore IR, Fox SP, Hollins AJ, Akhtar S. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 3: 147-155, 2006.
20. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res 83: 234-246, 2009.
21. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104: 403-411, 2009.
22. Hausenloy DJ, Baxter G, Bell R, Bøtker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 105: 677-686, 2010.
23. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 8: 619-629, 2011.
24. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T, Itoh N. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150: 4625-4633, 2009.
25. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARγ-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425, 2007.
26. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, Kishore R, Zhu Y, Qin G, Silver M, Thorne T, Eaton L, Masuda H, Asahara T, Losordo DW. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113: 1605-1614, 2006.
27. Jennings RB. Commentary on selected aspects of cardioprotection. J Cardiovasc Pharmacol Ther 16: 340-348, 2011.
28. Katare R, Caporali A, Emanueli C, Madeddu P. Benfotiamine improves functional recovery of the infarcted heart via activation of prosurvival G6PD/Akt signaling pathway and modulation of neurohormonal response. J Mol Cell Cardiol 49: 625-638, 2010.
29. Kawata H, Yoshida K, Kawamoto A, Kurioka H, Takase E, Sasaki Y, Hatanaka K, Kobayashi M, Ueyama T, Hashimoto T, Dohi K. Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C in the rat ischemic myocardium. Circ Res 88: 696-704, 2001.
30. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635, 2005.
31. Kucia M, Dawn B, Hunt G, Guo Y, Wysoczynski M, Majka M, Ratajczak J, Rezzoug F, Ildstad ST, Bolli R, Ratajczak MZ. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 95: 1191-1199, 2004.
32. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 85: 1373-1416, 2005.
33. Li Y, Hiroi Y, Ngoy S, Okamoto R, Noma K, Wang CY, Wang HW, Zhou Q, Radtke F, Liao R, Liao JK. Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation 123: 866-876, 2011.
34. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClister DM Jr, Su H, Gannon J, MacGillivray C, Lee RT, Sinusas AJ, Spinale FG. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290: H232-H239, 2006.
35. Liu SQ, Tefft BJ, Liu C, Zhang B, Wu YH. Regulation of hepatic cell mobilization in experimental myocardial ischemia. Cell Mol Bioeng 4: 693-707, 2011.
36. Liu SQ, Tefft BJ, Roberts D, Schuster DJ, Wu A, Zhang D. Cardioprotective mechanisms activated in response to myocardial ischemia. Mol Cell Biomech 8: 319-338, 2011.
37. Liu SQ, Wu YH. Liver cell-mediated alleviation of acute ischemic myocardial injury. Front Biosci E2: 711-724, 2010.
38. Liu SQ, Alkema PK, Tieché C, Tefft BJ, Liu DZ, Li YC, Sumpio BE, Caprini JA, Paniagua M. Negative regulation of monocyte adhesion to arterial elastic laminae by signal-regulatory protein alpha and SH2 domain-containing protein tyrosine phosphatase-1. J Biol Chem 280: 39294-39301, 2005.
39. Liu SQ, Tefft BJ, Zhang A, Zhang LQ, Wu YH. Formation of smooth muscle α actin filaments in CD34-positive bone marrow cells in elastic lamina-dominant matrix of arteries. Mat Biol 27: 282-294, 2008.
40. Liu SQ, Tefft BJ, Kharitonenkov A, Ren Y, Zhang LQ, Wu YH. Fibroblast growth factor 21 mediated protection of ischemic myocardium (Abstract). Circ Res 109: AP278, 2011.
41. Liu SQ, Liu C, Zhang B, Ren Y, Zhang LQ, Zhang D. Cardioprotective role of ischemia-induced trefoil factor 3 (Abstract). Circulation 124: A13509, 2011.
42. Lotz C, Liem D, Ping P. New frontiers in myocardial protection: a systems biology approach. J Cardiovasc Pharmacol Ther 16: 285-289, 2011.
43. Martins PN, Theruvath TP, Neuhaus P. Rodent models of partial hepatectomies. Liver Int 28: 3-11, 2008.
44. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 276: 60-66, 1997.
45. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 50: 280-289, 2011.
46. Moore MM, Goldman J, Patel A, Chien S, Liu SQ. Role of tensile stress and strain in the induction of cell death in experimental vein grafts. J Biomech 34: 289-297, 2001.
47. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94: 7-16, 2004.
48. Muzumdar RH, Huffman DM, Calvert JW, Jha S, Weinberg Y, Cui L, Nemkal A, Atzmon G, Klein L, Gundewar S, Ji SY, Lavu M, Predmore BL, Lefer DJ. Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol 30: 1940-1948, 2010.
49. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206, 2000.
50. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98: 10344-10349, 2001.
51. Osypiw JC, Allen RL, Billington D. Subpopulations of rat hepatocytes separated by Percoll density-gradient centrifugation show characteristics consistent with different acinar locations. Biochem J 304: 617-624, 1994.
52. Paulsen FP, Woon CW, Varoga D, Jansen A, Garreis F, Jäger K, Amm M, Podolsky DK, Steven P, Barker NP, Sel S. Intestinal trefoil factor/TFF3 promotes re-epithelialization of corneal wounds. J Biol Chem 283: 13418-13427, 2008.
53. Przyklenk K, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther 16: 255-259, 2011.
54. Ryde'n M. Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 66: 2067-2073, 2009.
55. Sands BE, Podolsky DK. The trefoil peptide family. Annu Rev Physiol 58: 253-273, 1996.
56. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 54: 289-296, 2005.
57. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM; National Heart, Lung, and Blood Institute, National Institutes of Health. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 124: 1172-1179, 2011.
58. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103: 2776-2779, 2001.
59. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5: 836-847, 2004.
60. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4: 721-734, 2003.
61. Tian Z, Zheng H, Li J, Li YF, Su H, Wang X. Genetically induced moderate Inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ Res 111: 532-542, 2012.
62. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Growth-factormediated cardiac stem cell activation in myocardial regeneration. Nat Clin Pract Cardiovasc Med 4, Suppl 1: S46-S51, 2007.
63. Vander Heide R. Clinically useful cardioprotection: ischemic preconditioning then and now. J Cardiovasc Pharmacol Ther 16: 251-254, 2011.
64. Vinten-Johansen J, Shi W. Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. J Cardiovasc Pharmacol Ther 16: 260-266, 2011.
65. Wang Y, Tao L, Yuan Y, Lau WB, Li R, Lopez BL, Christopher TA, Tian R, Ma XL. Cardioprotective effect of adiponectin is partially mediated by its AMPK-independent antinitrative action. Am J Physiol Endocrinol Metab 297: E384-E391, 2009.
66. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478, 2006.
67. Wong WM, Poulsom R, Wright NA. Trefoil peptides. Gut 44: 890-895, 1999.
68. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151, 2003.
69. Ytrehus K, Liu Y, Tsuchida A, Miura T, Liu GS, Yang XM, Herbert D, Cohen MV, Downey JM. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol Heart Circ Physiol 267: H2383-H2390, 1994.
70. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114, 2006.
71. Zou Y, Takano H, Mizukami M, Akazawa H, Qin Y, Toko H, Sakamoto M, Minamino T, Nagai T, Komuro I. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 108: 748-753, 2003.